Continuing to reshape its business, Sanofi (NYSE:SNY) is in talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for €1.9B.

That’s after spending more than $16B to buy biotech company Ablynx and U.S. haemophilia specialist Bioverativ.

This week, Sanofi also sold some brands to Charterhouse Capital Partners’ Cooper-Vemedia drugs manufacturing arm for €158M.



READ SOURCE

MUST READ  Merkel provides some help to May – Sell opportunity on GBP/USD?
SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here